TenNor Therapeutics (Suzhou) Limited recorded unanimous shareholder support for every motion tabled at its 2025 annual shareholders’ meeting (ASM) held on 29 June 2026 in Suzhou, Jiangsu.

The poll-based voting covered six ordinary resolutions, each receiving 17.10 million votes in favour—representing 100.00% of votes cast and 32.68% of the company’s total issued share capital. No votes were recorded against or as abstentions.

Key resolutions approved: • 2025 work report of the Board of Directors. • 2025 performance report of independent non-executive directors. • 2025 annual financial report. • 2025 profit distribution plan. • Remuneration plan for the current Board session. • Engagement of the Company’s auditor for FY 2026.

As at the meeting date, TenNor had 52.33 million H shares in issue, with no treasury shares outstanding.

Executive Director and Chairman Dr. Ma Zhenkun presided over the meeting; attending directors included Dr. Song Gaoguang, Dr. Li Leping and Dr. Ni Lin. Independent non-executive director Mr. Lee Wai Kong, Albert was absent due to official duties. Tricor Investor Services Limited and two shareholder representatives acted as scrutineers, validating the poll results.